Acetylfentanyl
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Acetylfentanyl is a synthetic opioid of the anilidopiperidine class. It is the simplest structural analog of fentanyl, carrying one fewer carbon in its acyl chain. It activates opioid receptors in the brain, suppressing pain signaling and slowing breathing.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
fentanyl, morphine, heroin +4 morefentanyl, morphine, heroin, oxycodone, hydromorphone, methadone, all mu-opioid receptor agonists show less
It was first synthesized in the late 1960s by Janssen and Gardocki during structure-activity studies of fentanyl.[1][2] In 2012–2013 it appeared on illicit markets as a research chemical, triggering 14 overdose deaths in Rhode Island within three months.[3] It is now Schedule I in the United States and largely displaced from the drug supply by fentanyl itself.
Subjective effects include profound pain suppression, euphoria, heavy sedation, anxiolysis, and a warmth that narrows consciousness. The experience mirrors fentanyl — pain and distress dissolve rapidly into a heavy, quiet calm — but compressed into a shorter window. Nausea, respiratory depression, and cognitive impairment are characteristic unsought effects.
Acetylfentanyl produces rapid physical dependence, and the gap between an active dose and a fatal dose is critically narrow[4][2] — 23 times narrower than fentanyl's and 10 times narrower than morphine's. Tolerance to euphoria builds faster than to respiratory suppression, so dose escalation tightens the margin toward fatal overdose. No controlled human studies exist — the evidence base is forensic case reports, postmortem toxicology, and animal pharmacology.
History[edit]
Discovery
Acetylfentanyl was first synthesized in the late 1960s by Janssen and Gardocki as part of systematic studies on the anilidopiperidine family.[1][2] It was found to be less potent than fentanyl and was never pursued for medical use. It remained an obscure laboratory entry for roughly four decades.
Illicit market emergence
In 2012–2013, acetylfentanyl appeared on illicit markets as a research chemical, with manufacturing concentrated in China.[2][1] Fourteen people died of overdose in Rhode Island in just three months,[3] prompting emergency scheduling. By 2015, 32 deaths had been documented across four EU member states,[5] and the compound had been found in heroin supplies across multiple US states.[6]
Scheduling and decline
The United States permanently placed acetylfentanyl in Schedule I in June 2017, citing over 57 confirmed deaths.[7] By 2016–2017 it had largely shifted from a standalone product to a manufacturing byproduct — found mainly as a trace contaminant in illicitly produced fentanyl.[8] Fentanyl itself now dominates the illicit opioid supply.
The name "acetylfentanyl" describes its chemistry directly: the acetyl group (a two-carbon chain) replaces fentanyl's propionyl group (three carbons). Unlike fentanyl, which accumulated dozens of street names across decades, acetylfentanyl has no widely recognized slang — it was a standalone market product for too brief a time. Its principal legacy is as an early warning: the 2013 Rhode Island cluster was among the first events to demonstrate that novel fentanyl analogs could appear on unregulated markets with lethal speed.
Chemistry[edit]
Structural class
Acetylfentanyl belongs to the anilidopiperidine class of synthetic opioids.[1][2] It is the simplest structural variant of fentanyl: where fentanyl carries a three-carbon propionyl group, acetylfentanyl carries a two-carbon acetyl group — one carbon shorter. This single-carbon difference reduces potency at the opioid receptor by approximately threefold.[9]
Molecular properties
Its molecular formula is C₂₁H₂₆N₂O (molecular weight 322.4 g/mol). It contains no asymmetric carbon centers, so no mirror-image forms exist. Like other anilidopiperidines, it is highly lipophilic — it crosses the blood-brain barrier rapidly, and postmortem studies confirm that brain concentrations exceed those in peripheral blood.[10]
Pharmacology[edit]
Mechanism of action
Acetylfentanyl is a full agonist at mu-opioid receptors, the same molecular target as morphine and fentanyl.[11][12] Activating these receptors quiets pain signals, generates reinforcing euphoria, and suppresses the brainstem centers that regulate breathing. The gap between an effective dose and a lethal dose is 23 times narrower than fentanyl's and 10 times narrower than morphine's.[4][2]
Pharmacokinetics
No human pharmacokinetic studies have been published. Acetylfentanyl is highly lipophilic — it crosses the blood-brain barrier rapidly. Postmortem studies confirm that brain tissue concentrations exceed those in peripheral blood.[10]
The liver breaks acetylfentanyl down through several pathways, including hydrolysis — yielding 4-ANPP, a controlled fentanyl precursor — and hydroxylation.[13][14] Detection of 4-ANPP in urine confirms acetylfentanyl exposure.[15] Blood samples remain stable for up to 9 months under refrigeration.[16]
Neuroscience[edit]
Where it acts
Acetylfentanyl activates opioid receptors in several brain regions at once. In the brain's reward circuit, this triggers a surge of dopamine, producing euphoria. In the brainstem — in the neurons that generate the breathing rhythm — the same activation suppresses respiratory drive and can cause breathing to stop.
Why it matters
With repeated use, the brain's craving system adapts faster than its pleasure system. The drive to seek the drug intensifies while the reward it delivers diminishes — producing escalating drug-seeking with less and less return.
Chronic opioid receptor activation also shifts the baseline of emotional wellbeing downward. Over time, use stops being about pleasure and becomes about escaping withdrawal misery.
Key unresolved questions include whether acetylfentanyl's shorter acyl chain changes how long it occupies the opioid receptor — which may partly explain its disproportionately narrow therapeutic index. It also remains unknown whether the divergence in pain-relieving versus respiratory-depressant potency across N-acyl fentanyl analogs[17] reflects differences in how the receptor signals in different tissues. No neuroimaging studies of acetylfentanyl have been published.
Subjective Effects[edit]
Acetylfentanyl produces a classical opioid experience: a rapid dissolving of physical pain and emotional distress into warmth, heavy sedation, and a narrowed, quieted consciousness. At lower amounts the effect is calm and analgesic; at higher amounts, sedation deepens quickly toward incapacitation.
Relative to fentanyl, acetylfentanyl is roughly one-third as potent per milligram but carries a disproportionately narrower safety margin — it is more dangerous per unit of intended effect. Compared to morphine, the experience arrives faster and ends sooner, with a safety margin 10 times narrower.
Effect Grid
At common doses, the full opioid effect constellation manifests: pronounced euphoria, significant sedation, and strong analgesia. Anxiety suppression is marked — emotional suppression flattens affective range, producing a state of insulated tranquility. Cognitive euphoria is prominent but accompanied by cognitive impairment: thought deceleration, reduced decision-making capacity, and focus suppression.
Physically, sedation dominates. Body high intensifies with strong tactile euphoria and spontaneous body sensations of warmth. Pupil constriction is clearly visible. Muscle relaxation is significant. Nausea becomes more likely, particularly in less tolerant individuals. Constipation, dry mouth, and appetite suppression are common. Respiratory depression becomes clinically relevant at this tier — monitoring is advisable.
Duration is 1–4 hours. Functional impairment is substantial. The compulsive redosing urge may emerge as effects begin to wane. Sexual arousal suppression is typical.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sedation · Bodily heaviness · Breathing alteration · Constipation · Muscle relaxation · Tactile euphoria · Nausea · Physical fatigue · Spontaneous body sensations · Dizziness · Dry mouth · Sexual arousal suppression · Temperature dysregulation · Appetite suppression · Excessive sweating · Heart rate perception changes · Vomiting · Yawning · Bodily lightness · Tingling / electric sensations · Watery eyes · Abnormal heartbeat · Involuntary body movements
Constipation · Muscle relaxation · Tactile euphoria · Nausea · Physical fatigue · Spontaneous body sensations · Dizziness · Dry mouth · Sexual arousal suppression · Appetite suppression · Excessive sweating · Heart rate perception changes · Vomiting · Yawning · Bodily lightness · Tingling / electric sensations · Watery eyes · Abnormal heartbeat · Involuntary body movements
Information processing suppression · Thought deceleration · Motivation suppression · Analysis suppression · Creativity suppression · Focus suppression · Language suppression · Memory suppression · Confusion · Memory fragmentation · Novelty suppression · Pattern recognition suppression · Suggestibility enhancement · Thought disorganization · Delusions of sobriety · Cognitive dysphoria · Amnesia
Analysis suppression · Creativity suppression · Focus suppression · Language suppression · Memory suppression · Confusion · Memory fragmentation · Novelty suppression · Pattern recognition suppression · Thought disorganization · Delusions of sobriety · Cognitive dysphoria · Amnesia
Dysphoria
Social disconnection · Social connection · Sociability enhancement · Cognitive disconnection
Timeline
Rapid rush of warmth and euphoria within 7–10 minutes. Onset is notably faster than sublingual, with a more pronounced initial wave. Analgesia and anxiolysis begin quickly.
Full opioid effect — sedation, euphoria, analgesia, and respiratory depression at maximum intensity. Pupil constriction is pinpoint. Cognitive impairment, thought deceleration, and emotional suppression are prominent.
Gradual waning of effects over 60–90 minutes. Residual sedation and mild analgesia persist. Compulsive redosing urge may peak during this phase as euphoria diminishes.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- fentanyl · morphine · heroin
Toxicity
Acute toxicity
Acetylfentanyl carries high acute toxicity — the gap between an effective dose and a fatal one is critically narrow.[4][2][9] Death results from respiratory depression: breathing slows progressively, then stops.[3][6][18] Acetylfentanyl also concentrates in brain tissue, consistent with its rapid onset.[10]
Co-intoxicants are the dominant variable in fatal outcomes. Single-agent deaths have clustered around 250–270 ng/mL,[19][4] but 96% of cases in one major death series involved multiple drugs,[18] with fatal concentrations spanning an enormous range.[20] Impaired driving cases in living subjects have shown levels as low as 1.0–9.2 ng/mL.[21]
Chronic toxicity
No published data exist on chronic toxicity specific to acetylfentanyl. Based on opioid class pharmacology, long-term use is expected to produce immune suppression, hormonal disruption, and gastrointestinal complications.inferred
Dermal exposure
Whether incidental skin contact can cause fatal overdose is consistent with regulatory statements, but no peer-reviewed case reports of fatal dermal absorption of acetylfentanyl specifically have been published.safety citation needed
Psychological risks
No controlled data on acetylfentanyl-specific psychological effects exist. Documented cases uniformly involve loss of consciousness and deep sedation.[22][12] Class-level risks of μ-opioid agonism include compulsive redosing, impaired judgment during intoxication, severe mood disturbance in withdrawal, and suicidal ideation.
Tolerance and dependence
Tolerance to acetylfentanyl's analgesic and euphoric effects builds with repeated use. Cross-tolerance extends to all opioids. Tolerance half-life is estimated at approximately 5 days, with full reset in about 1.5 weekssafety citation needed — class-level estimates not verified for acetylfentanyl specifically.
Physical dependence develops with repeated use. Stopping produces withdrawal: runny nose, sweating, muscle pain, diarrhea, nausea, and insomnia.inferred The DEA permanently scheduled acetylfentanyl partly on the basis of its high abuse potential,[7] and reinforcing properties of fentanyl analogs including acetylfentanyl have been specifically investigated.[23]
Drug interactions
The dominant risk is synergistic respiratory depression — two or more depressants together suppress breathing far more than either alone. This mechanism accounts for the majority of documented deaths: 96% of cases in one major series involved multiple drugs.[18]
Alcohol and benzodiazepines compound respiratory depression directly — documented in multiple fatality series.[18][20] GHB/GBL and ketamine carry lethal risk through complementary depressant mechanisms.[22] Tramadol adds combined opioid agonism and risk of serotonin overload. CYP3A4 inhibitors such as ketoconazole, ritonavir, and erythromycin may raise acetylfentanyl levels and worsen respiratory depression.inferred
Contraindications
No acetylfentanyl-specific contraindication data exist — all are derived from opioid class pharmacology.inferred Any pre-existing breathing difficulty (COPD, sleep apnea, asthma flare) dramatically raises fatal overdose risk, as respiratory depression is the primary lethal mechanism. Concurrent use of any CNS depressant — benzodiazepines, alcohol, GHB, barbiturates, other opioids — carries lethal synergistic respiratory depression risk.[18]
Liver impairment slows acetylfentanyl's clearance, potentially prolonging and intensifying effects.inferred Head injury or raised intracranial pressure is worsened by opioid-induced CO₂ buildup and brain swelling.inferred Opioids cross the placenta and can cause neonatal withdrawal syndrome, making pregnancy a relative contraindication.inferred
Harm Reduction[edit]
Forms & Identification
Acetylfentanyl cannot be visually distinguished from fentanyl, heroin, or other white-to-off-white powders. Because it increasingly appears as a contaminant in illicit fentanyl rather than a standalone product,[2] it may be present without anyone knowing. Fentanyl test strips detect acetylfentanyl, but a positive result cannot distinguish between fentanyl and its analogs — it confirms an anilidopiperidine is present. A negative result does not guarantee safety; test sensitivity varies by analog and concentration.
Guidelines
- Test all substances with fentanyl test strips before use
- Start with the smallest measurable amount — the therapeutic index does not forgive estimation
- Never use alone; ensure a sober person with naloxone is present
- Keep naloxone immediately accessible — not in another room, not in a bag
- Avoid mixing with any other depressant, including alcohol
- Wait for the full duration of effects before considering redosing — the short duration invites compulsive redosing, which rapidly accumulates respiratory risk
- Use in a physically safe position: seated or on the side, not standing
Set & Setting
Acetylfentanyl should never be used alone. The rapid onset and narrow therapeutic index mean the window between functional consciousness and respiratory arrest is extremely short. A sober person capable of recognizing overdose and administering naloxone is a minimum safety requirement. Isolated or physically hazardous environments compound the risk.
Aftercare & integration. Following acetylfentanyl use, drink fluids, eat lightly, and rest. Constipation is common after opioid use and may persist for 1–2 days. Monitor breathing and alertness for several hours after effects appear to subside — re-sedation is possible if naloxone was given and later wears off.
The reinforcing quality of opioid euphoria makes honest self-assessment important. If use was motivated by emotional pain, or if the compulsive redosing urge was difficult to resist, these patterns warrant attention before they become entrenched. Professional support is appropriate at any stage.
Recovery & Support
Acetylfentanyl dependence follows the same trajectory as other opioid dependencies: escalating use, life narrowing around the substance, and withdrawal avoidance as the primary motivator. Evidence-based options include:
- Medication-assisted treatment: buprenorphine (Suboxone) and methadone reduce cravings and prevent withdrawal. Naltrexone is an option after full detoxification.
- Professional detoxification: Medical supervision during withdrawal reduces risk and discomfort. Stopping abruptly without medical support is not recommended.
- Peer support: SMART Recovery, Narcotics Anonymous, and harm reduction organizations offer community-based support.
- Mental health care: depression, anxiety, and trauma are common in opioid use disorder and benefit from parallel treatment.
Recovery is not conditional on hitting a defined low point. Support resources exist at every stage.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing has slowed dramatically, become irregular, or stopped
- Lips, fingertips, or skin have turned blue or gray
- Person is unresponsive to voice, sternal rub, or pain
- Deep snoring or gurgling sounds (airway obstruction)
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone (nasal spray or injection) — do not wait to see if the person improves on their own
- 3. If no response after 2–3 minutes, administer a second dose of naloxone
- 4. Place the person in the recovery position (on their side, mouth angled downward) to prevent choking
- 5. Stay with the person — acetylfentanyl's effects may outlast naloxone's duration, causing re-sedation
- 6. Begin rescue breathing if trained and if the person is not breathing
What to tell the dispatcher:
- "Possible opioid overdose"
- What was taken (if known), how much, and when
- Whether naloxone has been given and how many doses
- Current breathing status and level of consciousness
- Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related offenses
Reversal agent: Naloxone (Narcan) reverses acetylfentanyl's respiratory depression. Multiple doses may be required — acetylfentanyl's effects can outlast a single naloxone dose. Naloxone is available without prescription in many jurisdictions.
Legal Status[edit]
Acetylfentanyl is controlled in most major jurisdictions, driven by documented overdose deaths from 2013 onward. It has no approved medical use anywhere.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporarily scheduled July 2015;[24] permanently placed June 2017 with 57+ confirmed deaths cited.[7] Prior to 2015, potentially subject to Federal Analogue Act. |
| Canada | CDSA Schedule I | Controlled under fentanyl and analogues provision.[25] A 3 kg seizure occurred in 2013.[11] |
| European Union | Subject to member state controls | EMCDDA–Europol joint risk assessment completed September 2015; joint report published June 2016.[5] Sweden, Germany, and Poland implemented controls following documented fatalities. |
| United Kingdom | Controlled | Two documented fatalities by August 2015. Covered by Psychoactive Substances Act 2016 and potentially by generic fentanyl analog provisions under the Misuse of Drugs Act 1971.citation needed |
| Australia | Expected Schedule 9 (Prohibited Substance) | Classification expected based on class membership but not independently confirmed.citation needed |
| Japan | Controlled under narcotics law | Documented fatalities and market detections from 2014–2015.[4] |
Analog and precursor considerations
Acetylfentanyl's main metabolite, 4-ANPP, is independently controlled as a fentanyl precursor — its presence in urine confirms acetylfentanyl exposure.[15] Acetylfentanyl is also frequently found as a manufacturing contaminant in illicitly produced fentanyl,[2] creating regulatory complications where structural analog control and precursor scheduling overlap.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice.
references
- [1] ^abcdJannetto PJ, Helander A, Garg U, Janis GC, Goldberger B, Ketha H (2019) The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union. — Clinical chemistry doi:10.1373/clinchem.2017.281626
- [2]
- [3] ^abcLozier MJ, Boyd M, Stanley C, Ogilvie L, King E, Martin C, Lewis L (2015) Acetyl Fentanyl, a Novel Fentanyl Analog, Causes 14 Overdose Deaths in Rhode Island, March-May 2013. — Journal of medical toxicology doi:10.1007/s13181-015-0477-9
- [4]
- [5]
- [6] ^abO'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM (2017) Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016. — MMWR. Morbidity and mortality weekly report doi:10.15585/mmwr.mm6643e1